featured-image

sutthirat sutthisumdang Piper Sandler has upgraded Teleflex ( NYSE: TFX ) to overweight, citing expected EPS growth in 2025. The investment bank said it believes UL sales in physician’s offices “are starting to find a bottom” and that “the franchise will be less of a revenue headwind starting in 2025.” It also sees the company benefitting from IABP “challenges” at Getinge and Barrigel becoming a “significant” revenue generator.

“With some of the earnings pressures easing next year and a modest valuation of less than 14x ‘25E on a P/E basis, we believe now is the time to upgrade the stock,” the analysts added in their note. Piper set its price target at $245. More on Teleflex Teleflex: Compelling, Despite Some Operational Hiccups Teleflex Incorporated (TFX) Q1 2024 Earnings Call Transcript Teleflex Incorporated 2024 Q1 - Results - Earnings Call Presentation Teleflex Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Teleflex.



Back to Health Page